← Back
Data updated: Mar 29, 2026
BIOCON PHARMA
CardiovascularInfectious DiseaseOncology
Generics
BIOCON PHARMA is a generic drug manufacturer focused on Cardiovascular, Infectious Disease, Oncology.
2006
Since
23
Drugs
-
Trials
328
Approved (2yr)
Top Drug Revenues Pro
Loading...
Revenue Over Time Pro
Loading...
Recent Activity
LIRAGLUTIDE 2026-02-24
MICAFUNGIN SODIUM 2026-02-24
LIRAGLUTIDE 2026-02-24
RIVAROXABAN 2026-02-20
TOFACITINIB CITRATE 2026-02-18
Labeling
TOFACITINIB CITRATE 2026-02-18
Labeling
TOFACITINIB CITRATE 2026-02-18
Labeling
TOFACITINIB CITRATE 2026-02-18
Labeling
SEC Filings
Pro
Loading...
Therapeutic Areas
Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5
Cardiovascular 25%
3 drugs
Infectious Disease 25%
3 drugs
Oncology 25%
3 drugs
Metabolic 17%
2 drugs
Neurology 8%
1 drugs
Pipeline Forecast
Loading...
Loading...
Upcoming Trial Milestones Pro
Loading...
Patent Cliff Pro
Loading...
Loading...
Loading...
Competitors by Therapeutic Area
Merck big-pharma
Oncology, Infectious Disease, Cardiovascular, Metabolic
Johnson & Johnson big-pharma
Oncology, Infectious Disease, Cardiovascular, Metabolic
Novo Nordisk big-pharma
Metabolic, Oncology, Cardiovascular, Infectious Disease, Neurology
AZURITY specialty
Cardiovascular, Oncology, Neurology, Metabolic, Infectious Disease
GE HEALTHCARE specialty
Infectious Disease, Neurology, Cardiovascular, Oncology
Active (19)
RIVAROXABAN LIRAGLUTIDE SACUBITRIL AND VALSARTAN PEMETREXED DISODIUM LENALIDOMIDE POSACONAZOLE MICAFUNGIN SODIUM TERIFLUNOMIDE DASATINIB ROSUVASTATIN CALCIUM DAPTOMYCIN MYCOPHENOLATE SODIUM ATORVASTATIN CALCIUM TACROLIMUS OXCARBAZEPINE SIMVASTATIN PRAVASTATIN SODIUM NOREPINEPHRINE BITARTRATE NITROFURANTOIN
Discontinued (3)
Company Info
- First Approval
- 2006-12-20
- Latest
- 2026-02-24
- Applications
- 28
FDA Sponsor Names
BIOCON PHARMABIOCON PHARMA LTD